Recent Company News

• 07:08 AM ET Jun 10, 2026
  

  CSPC Pharmaceutical Group's phase III clinical trial of KN206 combined with HB1801 for breast cancer meets primary endpoint (HK$7.26, 0.00)

• 02:09 AM ET Jun 05, 2026
  

  StreetAccount Sector Summary - China Healthcare May Recap

• 08:50 PM ET Jun 03, 2026
  

  CSPC Pharmaceutical Group upgraded to overweight at Zhongtai International (3-Jun, timing uncertain) (HK$7.25, 0.00)

• 06:28 AM ET Jun 02, 2026
  

  CSPC Pharmaceutical Group obtains NMPA clinical trial approval for SYS6063 injection (HK$7.57, 0.00)

• 06:25 AM ET Jun 02, 2026
  

  CSPC Pharmaceutical Group presents phase I clinical data of SYS6043 at 2026 ASCO (HK$7.57, 0.00)

• 08:07 PM ET May 31, 2026
  

  Alphamab Oncology presents phase III KN026 neoadjuvant HER2+ breast cancer study at ASCO 2026 (HK$9.10, 0.00)

• 08:22 AM ET May 29, 2026
  

  CSPC Pharmaceutical Group receives $1.2B upfront from AstraZeneca under agreement announced 30-Jan

• 05:06 AM ET May 29, 2026
  

  NMPA approves marketing of CSPC Pharmaceutical and Alphamab Oncology's Ennituo to be combined with chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma (HK$7.50, 0.00)

• 03:27 AM ET May 29, 2026
  

  Street Takeaways - CSPC Pharmaceutical Group Q1 earnings (HK$7.48, +0.52)